Lack of dystrophin results in skeletal muscle dystrophy and dilated cardiomyopathy in humans and animal models. To achieve a basic understanding of the natural development of cardiomyopathy in different dystrophinopathy mouse models, left and right ventricular heart function was assessed at different ages in three dystrophinopathy mouse models (mdx, mdx/utrn +/À model and mdx/utrn À/À ) using magnetic resonance imaging. Left ventricular function was significantly decreased, already at 2 months in the most severely affected mdx/ utrn À/À mice. Furthermore, whereas heart function was stable in wild-type mice over time, both mdx and mdx/utrn +/À showed a clear decrease at 10 months of age, most prominently in the right ventricle. Therefore magnetic resonance imaging is an adequate technique to determine heart function in dystrophinopathy mouse models and can be used to assess the effect of potential therapies. Ó 2011 Elsevier B.V.
Introduction
Duchenne muscular dystrophy (DMD) is a severe, progressive muscle wasting disorder that affects around 1 in 3500 newborn boys [1] . It is caused by a genetic defect in the DMD gene located on the X-chromosome (Xp21), encoding the dystrophin protein. Frame-shifting mutations or premature stop codons cause the loss of functional dystrophin [2] . Dystrophin is located inside the muscle fibres and is part of the dystrophin-associated protein complex (DAPC), which has an important role in providing mechanical stability to the skeletal muscle fibres during contraction [3] .
Symptoms in DMD patients generally start before the age of six and involve weakness of the lower extremities muscles leading to loss of ambulation around the age of 10-15. Involvement of the diaphragm causes the need of assisted ventilation in the late teens [4] . Most of the patients also exhibit clinically relevant cardiac involvement. Electrocardiogram (ECG) abnormalities, depressed left ventricular function and a dilated left ventricle are found in >95% of patients [5, 6] . Most patients stay asymptomatic till late stages of heart failure, probably due to lack of physical activity, but dilated cardiomyopathy eventually causes death in 10-20% of patients, and is becoming more important due to improvements in clinical care [7] [8] [9] .
Several mouse models exist for dystrophinopathy [10] . The most common model is the mdx (C57Bl/10ScSn-DMD mdx /J) mouse. These mice have a premature stop codon in exon 23, leading to the production of a truncated, non-functional dystrophin protein [11] . However, due to a better muscle regenerative capacity and upregulation of the dystrophin homologue utrophin, mice have only a mild phenotype compared to humans, and have only a slightly shorter life expectancy compared to wild-type mice [12] . Nevertheless, muscle function is impaired and muscles exhibit a dystrophic phenotype. A more severely affected mouse model is the mdx/utrn À/À mouse, lacking both dystrophin and utrophin. The severe phenotype of these mice is more comparable to humans and these mice have an average life expectancy of around 2-3 months [13] . This very short life span makes it difficult to use these animals for study purposes. Heterozygote mice with one functional utrophin copy (mdx/utrn +/À mice) exhibit an intermediate phenotype. Muscle inflammation and fibrosis is worse compared to mdx mice, but life span is longer than that of mdx/ utrn À/À mice [14] . Although the phenotype of mdx/utrn
and mdx/utrn À/À mice is more comparable to humans, a disadvantage of these mice is the heterogeneity in the background of these mice [15] , which causes larger variations between individual mice.
Although some studies have been performed to assess heart function in mouse models for DMD, they mainly used mdx mice and the results are sometimes inconsistent. In young mdx mice no differences in cardiac function are found when compared to age-matched wild-type mice. Dilated cardiac myopathy starts to develop when mice are ageing, becoming prominent at 9-10 months of age when changes in functional parameters (e.g. decrease of shortening fraction) are found using electrocardiography (ECG) or echocardiography [16] [17] [18] [19] . In contrast, Li et al. did not observe this functional decline by ECG even in 10 months old mice, and only found alterations with more sensitive methods (cardiovascular magnetic resonance tagging) [20] . Furthermore, some studies describe an increase in left ventricular internal diameter (end systolic and/or end diastolic) [17, 19] . In addition, around the age of 6 months finding on cardiac perfomance vary from virtually no decline in mdx mice [17] to some [16] or even prominent deterioration in cardiac function [21] . This may be because most studies use only ECG analysis, which is a global method to determine cardiac function, using geometric assumptions for the calculation of functional parameters. This technique is therefore less suitable to detect changes in ventricular shape. Magnetic resonance imaging (MRI) has been shown to be a more sensitive and accurate technique for high resolution imaging and determination of ventricular function, both in normally shaped hearts and in hearts deformed by diseases [22] [23] [24] .
Knowledge about cardiac involvement in dystrophinopathy mouse models is important to assess their validity as disease models, since cardiomyopathy is a prominent feature in DMD patients. Furthermore, a basic understanding of good biomarkers for heart pathology is needed to be able to monitor therapeutic effects of potential treatments in animal models on the heart muscle.
Therefore, the aim of this study is to compare the cardiac involvement of different mouse models for DMD and the development of cardiomyopathy in these mouse models over time using cine-MRI with retrospective ECG-gating.
Materials and methods

Animals
C57Bl/10ScSnJ, mdx (C57Bl/10ScSn-DMD mdx /J), mdx/ utrn +/À and mdx/utrn À/À were obtained from our own breeding facilities. All experiments were approved by the animal ethical experimental committee of the Leiden University Medical Center (LUMC) (project 09185). Mice were housed in individually ventilated cages in the animal facility of the LUMC and transported to the animal facility of the Faculty of Science of the University of Leiden 7 days before analysis for acclimatisation. Mice received food and drink ad libitum.
The four different genotypes were assessed in a crosssectional design: wild-type (C57Bl/10ScSnJ, mdx (C57Bl/ 10ScSn-DMD mdx /J), and mdx/utrn +/À mice were analysed at 2, 6 and 10 months of age (n = 6 per time-point) and mdx/utrn À/À at 2 months of age (n = 6). Each group consisted of 3 male and 3 female mice. Mice were anaesthetized by inhalation of 2% isoflurane in 1:1 oxygen:air. Respiration rate was monitored with a respiratory pad and kept constant at 50-80 respirations per minute during the MRI scan. After the analysis, anaesthetized mice were sacrificed by cervical dislocation. Hearts were isolated and snap frozen in liquid nitrogen-cooled 2-methylbutane (Sigma-Aldrich, The Netherlands).
MRI
Mice were imaged using a vertical 9.4 T magnet with 89 mm bore size, equipped with a 1 T/m gradient system (Bruker BioSpin, Germany) using a quadrature birdcage coil with an inner diameter of 30 mm.
Bruker Paravision 5.0 software was used for image acquisition. A self-gated cine MRI sequence was used (Intragate) based on a navigator-based retrospective gating technique, followed by sorting data points according to their origin in the cardiac cycle [25] . Imaging parameters were with flip angle 10°; repetition time 8.5 ms; echo time 1.86 ms; field-of-view 2.56 Â 2.56 cm 2 ; matrix 192 Â 192; in-plane resolution 133 lm; slice thickness 1 mm; 8-9 short-axis slices, number of repetitions 200; total acquisition time approximately 30 min. The navigator echo was placed in-slice. Images were reconstructed to 18 frames per heart cycle.
MRI data analysis
Images were analysed with MASS for mice software (developed in-house at the LUMC, Division of Image Processing (LKEB)) [26, 27] . Endocardial and epicardial contours were drawn manually for both left and right ventricle. End diastolic (ED) and end systolic (ES) phase were determined by the software and cardiac function parameters (ED and ES mass, EDV, ESV and EF) were calculated automatically. Ventricular mass is defined as the average of the ED and ES mass. As an internal control, a maximum mass difference of 10% was accepted. This was achieved for all mice. End diastolic volume (EDV) and end systolic volume (ESV) were determined, and stroke volume (SV = EDVÀESV), ejection fraction (EF = (SV/EDV) Â 100%) and cardiac output (CO = SV Â heart rate) were calculated from these parameters.
Statistical analysis
Data are represented as mean ± SD. Statistical analyses were performed using SPSS 17.0.2 (SPSS, Inc., Chicago, IL, USA). Statistical significance between all four groups at 2 months was assessed using one-way analysis of variance (ANOVA), followed by a Bonferroni correction for multiple testing in case of significance (P < 0.05). C57Bl/ 10ScSnJ, mdx (C57Bl/10ScSn-DMD mdx /J), and mdx/ utrn +/À mice were compared over time with two-way ANOVA, followed by a LSD correction for multiple testing, in case of significance (P < 0.05).
Histology
Sections of 8 lm were cut with a Shandon cryotome (Thermo Fisher Scientific Co., Pittsburgh, PA, USA) on Superfrost Plus slides (Thermo Fisher Scientific, Menzel-Gläser, Germany) along the entire length of the heart with a minimum interval of 240 lm between the sections. Slides were fixed for 5 min in ice-cold acetone and stained using the Masson's Trichrome staining (SigmaAldrich, The Netherlands). Pictures were taken at 2.5Â magnification with a Leica DC500 camera and Leica IM50 software connected to a Leica DM LB light microscope (Leica Microsystems, The Netherlands). For blending and background correction Adobe Photoshop CS3 version 10.0.1 was used.
Results
Cardiac function is impaired in 2 months old mdx/utrn À/À mice
Heart function of all mice strains was determined at the age of 2 months. At this time point, no differences in ventricular function were found between mdx, mdx/utrn
and wild-type (C57Bl/10ScSnJ) mice ( In the right ventricle, the difference in function was less marked (Fig. 2) , with only the EF showing a significant decrease in comparison with all other mouse strains.
Cardiac function declines in mdx and mdx/utrn +/À mice during ageing
For wild-type, mdx and mdx/utrn +/À mice, heart function was also determined at 6 and 10 months of age. Wild-type mice showed a stable heart function during ageing for both the left and the right ventricle (Figs. 3 and 4) . In contrast, the mdx and mdx/utrn +/À mice showed a deterioration of the left ventricular function with age. Whereas at 2 and 6 months the heart function was still comparable to that of wild-type mice, a decrease in SV was seen at the age of 10 month, which was significant in mdx mice, but not in mdx/utrn +/À mice due to larger interindividual variation. Cardiac output, as computed by stroke volume times heart rate, was not decreased, which might by explained by a compensatory increase in heart rate in the mdx/utrn +/À mice (Fig. 5 ). The ageing effect was much more pronounced in the right ventricle (Fig. 4) . While right ventricular function was stable over time in wild-type mice, a small decrease was already visible at the age of 6 months in mdx and mdx/utrn +/À mice, which became more prominent at 10 months of age. For both mdx and mdx/utrn +/À mice the EF started to decline at 6 months and was markedly decreased at 10 months of age. The CO remained stable over time in wild-type mice, but a trend towards a decline at 10 months was seen. In both mdx and mdx/utrn +/À a significant lowering of SV compared to wild-type mice was seen, which mainly seemed to be at the age of 10 months. In the EDV no differences were observed.
The impairment in heart function as seen in mdx and mdx/utrn +/À mice correlated with the formation of fibrotic tissue in these mice during ageing (Fig. 6) . Whereas minimal amounts of fibrosis were seen in both young and older wild-type mice, fibrotic areas are prominent in 10 months old mdx mice. Mdx/utrn +/À mice already showed some fibrotic tissue at 2 months of age and this was clearly visible in mice of both 6 and 10 months of age.
Discussion
The majority of DMD patients exhibits a decline in cardiac function, starting around the age of 10 and gradually worsening during disease progression. Currently, several therapies for DMD are under development. Most prominent are antisense oligonucleotides (AONs) which aim to skip the targeted exon to correct the disrupted reading frame in DMD [10, [28] [29] [30] . However, the AONs currently tested in clinical trials lead to exon skipping in skeletal muscle, but hardly in the heart [31] . Because AONs are not yet very effective in the heart, cardiac problems may become a more prominent and disabling aspect of the disease for patients treated with AONs (should exon skipping become clinically available). In addition, due to improvements in health care, the life expectancy of DMD patients is increasing and cardiac problems become more and more the primary cause of death. Recent research in mdx mice has shown that rescue of the diaphragm function might be enough to rescue also heart function [32] . Nevertheless the (partial) rescue of skeletal function by the exon skip therapy might cause the patients to become more active, thereby increasing the workload on the heart, as has been observed in animal models with a microdystrophin transgene [33] . Therefore potential therapies should not only (A) Ejection fraction: in wild-type mice EF is stable over time. Mdx mice showed a significant decrease at 10 months compared to 2 months, but due to variation this was not significant compared to age-matched wild-type mice. (B) Cardiac output: no differences were observed between all genotypes and age groups. (C) Stroke volume: both mdx and mdx/utrn +/À mice, but not wild-type mice, showed a decrease in SV at the age of 10 months, but due to individual differences this was only significant in mdx mice. (D) End diastolic volume: no differences were observed between all genotypes at all ages. * P < 0.05. +/À mice showed a marked decrease in EF at the age of 10 months. This decline was not observed in wild-type mice. (B) Cardiac output: whereas CO was stable over time in wild-type mice, a trend towards a decline was seen in aged mdx and mdx/utrn +/À mice. (C) Stroke volume: SV was stable over time in wild-type mice, but impaired in mdx and mdx utrn +/À mice. (D) End diastolic volume: a small increase in EDV was observed in ageing mdx and mdx/utrn +/À mice, but due to large individual variations this was not significant compared to wild-type mice. * P < 0.05 vs wild-type mice. ** P < 0.01 vs wild-type mice at 10 months.
address skeletal muscle, but also the heart. To study the effect of these therapies on the heart a basic understanding of the heart function of the used models is necessary. Previous studies have shown that, although global heart function appears normal as assessed by global methods (e.g. conventional ECG), more sensitive methods can detect cardiac changes in early stages of the disease. In mdx mice cardiovascular magnetic resonance (CMR) tagging revealed functional alterations (a decrease in myocardial wall strain and torsion) in 10 months old mice [20] . In 25 weeks old GRMD dogs a decrease in function (decrease in myocardial velocity gradient) tissue Doppler imaging (TDI), despite normal ECGs [34] . Also in humans TDI has been able to detect alterations while conventional echocardiograms remained normal [35] . This indicates more sensitive methods are needed to detect cardiomyopathy early and follow while ageing. MRI is a widely used technique to study heart function with high resolution in both humans and animals. In this study we showed it can be used to follow the development of cardiac decline in different mouse models for DMD.
The mdx/utrn À/À mouse is the most severely affected mouse model. These mice have a life expectancy of approximately 8-10 weeks and by that time clear impairment of muscle function is seen. These mice have been not yet been well characterised with respect to cardiac involvement. Using histological analysis, some studies found minimal amounts of fibrosis and necrosis around the age of 10 weeks in the mdx/utrn À/À model, and no signs of dilated cardiomyopathy, comparable to age-matched mdx mice, [13] whereas others did find inflammation, cardiomyocyte . Heart rate was stable in ageing wild-type mice, but increased in aged mdx and mdx/utrn +/À mice. At 2 months of age no differences in heart rate were observed, but at the age of 10 months heart rate was increased in mdx and mdx/utrn +/À mice compared to wild-type. * P < 0.05.
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. Fibrosis is clearly visible in aged mdx and mdx/utrn +/À mice, whereas wild-type mice show minimal fibrotic tissue at the same age. While wild-type mice showed minimal amounts of fibrosis at the age of ten months, clear fibrotic areas (blue) were visible mdx and mdx/utrn +/À mice at this age. These already became visible in mdx/utrn +/À mice at the age of 2 and 6 months. Also 2 months old mdx/utrn À/À mice show some fibrotic areas, although to a lesser extend as mdx/utrn +/À mice. The immobility of the animals might play a role in the relatively little formation of fibrosis in the mdx/utrn À/À mice. Representative examples are shown for each group. degeneration and fibrosis in both mdx as mdx/utrn À/À mice of the same age [36] . However ECGs of 2 months old mdx/ utrn À/À mice were abnormal (decrease in S/R wave ratio) [16] . Furthermore contractile dysfunction of right ventricular muscles was worse in mdx/utrn À/À mice than in mdx mice [37] . The severe scoliosis of these mice has an effect on the anatomical position of the heart and thereby hampers the electrophysiological monitoring of cardiac function by ECG. However, with MRI it is possible to reliably quantify cardiac volumes and function without geometrical assumptions in these mice. Analysis clearly revealed that the skeletal muscle impairment was also reflected by a large decrease in cardiac function of both the left and the right ventricle. In the left ventricle a decline in stroke volume was observed. Patient-studies have shown the same pattern: heart failure with a preserved ejection fraction, probably due to left ventricular hypertrophy and increased muscle mass [38] . There was also a decrease in EDV, whereas an increase is expected if cardiac function declines. This can be explained by the cardiac mass of the left ventricle, which was also significantly lower in the mdx/utrn À/À mice compared to all other genotypes. The decrease in right ventricular function was less marked. This might be due to the severe respiratory problems seen in these mice, which results in a relatively lower workload on the right ventricle compared to the left ventricle, since the left ventricle must compensate for the decreased oxygen supply. Furthermore there is a large phenotypical variation between individual mice.
In addition to impairment of skeletal muscle function, the mdx mouse model also presents with heart failure. There have been some studies which assessed heart function in mdx mice. ECG abnormalities have been found at the age of 6 months. They showed a decreased S/R wave ratio compared to control mice [16] . These changes are similar to those found in the ECGs of the majority of DMD patients [39] . Left ventricular dysfunction (dilated cardiomyopathy) was seen in older mdx mice. At the age of 6-8 months, mild changes (decreased ejection fraction (EF) and cardiac output (CO)) were found, which became more prominent from the age of around 9-10 months [17, 18, 32, 40] . Furthermore mdx mice of this age showed a large increase in interstitional fibrosis compared to wildtype mice [18] . Right ventricular dysfunction seems to precede left ventricular dysfunction, as there was a clear decrease in EF and CO already at the age of 6 months [32] . Our findings support these findings, as we report that whereas wild-type mice have stable heart function during ageing, mdx mice showed a clear cardiomyopathy at the age of 10 months. In the left ventricle this was reflected by a decrease in stroke volume. The stroke volume (SV) is the difference between the end diastolic volume (EDV) and the end systolic volume (ESV), whereas the ejection fraction (EF) is both dependent on the EDV and the SV. This might be an explanation why differences in one parameter are not always reflected in the other parameters. Cardiac output (CO) is dependent on the heart rate of the mice. Although a decrease of SV in aged mdx and mdx/ utrn +/À mice was observed, this was not accompanied by a decrease in CO. The increase in heart rate observed in these mice, might be a reason for this, as a compensatory mechanism for the decrease in SV. This must be said with some precaution, since the mice were anaesthetized. However, previous studies showed that isoflurane anaesthesia has a large influence respiration rate, but heart function as measured with cine-MRI was independent of anaesthesia depth [34] . Whereas small indications of cardiomyopathy were seen in the left ventricle, it was marked in the right ventricle as was reflected by a significant decline or a trend towards a functional decrease in almost all functional parameters. This is compatible with previous studies, which showed an earlier and more pronounced functional decline of the right ventricle compared with the left ventricle [17, 18, 32, 40] .
A small limitation of the study is the observation that the determined CO in the right ventricle is smaller than in the left ventricle in all mice. This is not a true difference, but the result of the more complex and irregular shape of the right ventricle. As a result, the right ventricle is not sampled perpendicularly to the ventricular wall in every slice using short-axis cine MRI, thereby underestimating the ventricle dimensions. Secondly, differentiation of the pulmonary and the tricuspid valves is difficult, resulting in larger analysis errors for right ventricle when compared to left ventricular measurements [41] . However, since this difference is similar for all mice (regardless of genotype, age group or gender) and all mice are analysed in the same way, this limitation does not affect the comparability between the different groups in this study.
A good comparison over time between different mouse models with varying levels of utrophin has not been done. We found the same pattern in mdx/utrn +/À mice as for mdx mice, i.e. a mild decrease in left ventricular function and a large decrease in right ventricular function at the age of 10 months. Surprisingly, although the skeletal function of these mice is more affected than that of mdx mice, (van Putten et al., unpublished observations) this was not seen in cardiac function. Furthermore the variation between individual mdx/utrn +/À mice was large. This is probably due to the heterogeneity in background of these mice [15] .
The functional decline in mdx and mdx/utrn +/À mice as was seen by MRI analysis, correlated with the amount of fibrosis seen in mice of the different genotypes and ages. Although it was increased compared to age matched mdx and wild-type mice, there seemed to be less fibrosis in mdx/utrn À/À mice compared mdx/utrn +/À mice of the same age. This might be due to the severe phenotype of the animals, which causes immobility and thereby less activity of the heart. The cardiomyopathy observed in the different DMD mouse models shows resemblance to DMD patients, but some discrepancies are also seen. Whereas in humans mainly the left ventricle is involved, in mice the effects are more pronounced in the right ventricle [7] . A possible explanation is the differences in underlying respiratory pathology in mice and humans. When humans develop respiratory problems, assisted ventilation is started, whereas in mice respiratory failure is not treated. A recent study has shown that in mice respiratory intervention had a beneficial effect on heart function too [32] .
In conclusion we have shown that MRI is a reliable tool to study heart function in dystrophinopathy mouse models and these mouse models exhibit a decline in cardiac function correlated with disease progression. Therefore these mice are a versatile tool to study the effect of potential therapies, like AON mediated exon skipping, on the heart, in the future.
